New study aims to measure Real-Life impact of chemo nerve damage

NCT ID NCT07315334

Not yet recruiting Knowledge-focused Sponsor: Paracelsus Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will assess physical function in 80 people with chemotherapy-induced peripheral neuropathy (CIPN) using tests like balance, walking, and grip strength. Researchers will compare these objective measures with patients' own symptom reports to develop better ways to track the condition. Healthy volunteers will also be included for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better, more objective ways to measure how CIPN affects daily life, helping doctors tailor treatments.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.